Attorney General Aaron M. Frey announced this morning a settlement with Sanofi-Aventis US LLC after scrutiny over the company’s pricing of insulin products.  Under the settlement, Mainers who are uninsured or who have commercial health insurance will be eligible to purchase monthly supplies of Sanofi insulin products through 2029 for $35. cash.  The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the US.

“Insulin is a life-sustaining medication and far too many Mainers struggle to find it,” said Attorney General Frey.  ‘My Office  will continue to closely monitor drug pricig and take action to protect consumers to ensure access to these essential medications.”

In addition to the $35. cash monthly prescription rate, Sanofi has agreed to implement an enrollment mesage program to assist pharamacists and patients in determining eligibility for its low-cost insulin.  The system will alert pharmacists about the patient’s eligibility for this low-cost alternative at pharmacy counters throughout Maine when patients are filling their preseciprtions.

To explore possible savings through the $35. cash program, residents should ask their pharmacist when filling their prescription.